5 Best Performing American Stocks in June 2026

In this article, we will list the 5 Best Performing American Stocks in June 2026. Please visit 10 Best Performing American Stocks in June 2026 if you would like to see the extended list and the methodology behind it.

Pixabay/Public Domain

5. TG Therapeutics, Inc. (NASDAQ:TGTX)

On July 6, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi in adults with treatment-resistant schizophrenia. The open-label study is designed to evaluate the efficacy and safety of Briumvi in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite standard-of-care antipsychotic treatment.

On June 23, Jefferies raised the firm’s price target on TG Therapeutics to $83 from $57 and kept a Buy rating on the shares. Jefferies said the Street “still underappreciates the significance” of Phase 1 subcutaneous Briumvi pharmacokinetic data as predictive of a Phase 3 outcome expected by year-end 2026 to early 2027. Jefferies also updated its model to be more bullish on the subcutaneous opportunity.

On June 9, TG Therapeutics announced topline Phase 1 data for Briumvi in patients with myasthenia gravis and the initiation of a Phase 2 trial evaluating Briumvi as maintenance therapy after induction with efgartigimod. At Week 24, 82% of patients achieved the Minimal Clinically Important Difference in MG-ADL, with a median time to MCID of 30 days, while mean MG-ADL improvement was 4.6 points. The Phase 2 trial is expected to enroll approximately 120 patients, with time to clinical worsening as the primary endpoint.

TG Therapeutics, Inc. (NASDAQ:TGTX) focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.